Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-15

Clinical Trial Update: Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial of CM310 injection for moderate-to-severe atopic dermatitis has completed; the update summarizes the study status and outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CM310

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED